CA
STLN

Cliff Asness’s Starling Oncology STLN Stock Holding History

Cliff Asness’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$264K Buy
48,597
+4,078
+9% +$17.1K ﹤0.01% 3686
2026
Q1 		$137K Sell
44,519
-3,553
-7% -$10.9K ﹤0.01% 3658
2025
Q4 		$171K Buy
48,072
+4,007
+9% +$14.9K ﹤0.01% 3388
2025
Q3 		$154K Buy
+44,065
New +$151K ﹤0.01% 3311

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Cliff Asness's STLN Position: Q2 2026 in Review

Cliff Asness increased its Starling Oncology (STLN) stake by 9.2% in Q2 2026, buying an estimated $17.1K and bringing the position to 48,597 shares worth $264K. The position accounts for ﹤0.01% of the portfolio, ranked #3686.

Cliff Asness first reported a position in STLN in Q3 2025 and has held it in 4 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Cliff Asness held 48,597 shares of Starling Oncology worth $264K as of Q2 2026.
  • Cliff Asness bought 4,078 Starling Oncology shares in Q2 2026, an estimated $17.1K.
  • Starling Oncology made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #3686 holding.
  • Cliff Asness first reported a position in Starling Oncology in Q3 2025 and has held it in 4 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.